Loxo Oncology Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 American Society of Clinica...
May 17 2017 - 5:00PM
– Company to Host Conference Call and Webcast on
Sunday, June 4th at 5:30PM CT –
Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company
innovating the development of highly selective medicines for
patients with genetically defined cancers, announced that study
investigators will present larotrectinib (LOXO-101) interim
clinical data across the RECIST-evaluable TRK fusion clinical trial
database from all three ongoing clinical trials in a late breaking
oral presentation at the ASCO Annual Meeting being held
on June 2 - 6, 2017 in Chicago, IL. This presentation was also
selected for inclusion in the ASCO Press Program. In addition, the
larotrectinib interim pediatric Phase I clinical data will be
highlighted in a separate oral presentation.
The schedule for the presentations is as follows:
Late Breaking Presentation Date & Time:
Saturday, June, 3, 2017, 1:15 – 4:15PM CTTitle:
The efficacy of larotrectinib (LOXO-101), a selective tropomyosin
receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion
cancers.Abstract Number: LBA2501 Session
Title: Developmental Therapeutics – Clinical Pharmacology
and Experimental Therapeutics Location:
E450abPresenter: David Michael Hyman,
M.D.
Presentation Date & Time: Monday, June, 5,
2017, 8:00 – 11:00AM CTTitle: A pediatric phase I
study of larotrectinib, a highly selective inhibitor of the
tropomyosin receptor kinase (TRK) family.Abstract
Number: 10510Session Title: Pediatric
Oncology IILocation:
S504Presenter: Theodore Willis Laetsch,
M.D.
Conference Call and Webcast Information Loxo
Oncology will host a conference call and live webcast with slides
and Q&A on Sunday, June 4, 2017 at 5:30PM CT to discuss the
larotrectinib data presented at ASCO. To participate in the
conference call, please dial (877) 930-8065 or (253) 336-8041 and
refer to 14447513. A live webcast of the presentation will be
available at http://ir.loxooncology.com/. A replay of the webcast
will be available shortly after the conclusion of the call and
archived on the company's website for 90 days following the
call.
About Larotrectinib (LOXO-101) Larotrectinib
(LOXO-101) is a potent, oral and selective investigational new drug
in clinical development for the treatment of patients with cancers
that harbor abnormalities involving the tropomyosin receptor
kinases (TRKs). Growing research suggests that the NTRK genes,
which encode for TRKs, can become abnormally fused to other genes,
resulting in growth signals that can lead to cancer in many sites
of the body. In an ongoing Phase 1 clinical trial, larotrectinib
has demonstrated encouraging preliminary efficacy. Larotrectinib is
also being evaluated in the NAVIGATE global Phase 2 multi-center
basket trial in patients with solid tumors that harbor TRK gene
fusions, and the SCOUT Phase 1/2 trial in pediatric patients,
including patients with advanced cancer, TRK gene fusions and
infantile fibrosarcoma. Larotrectinib has been granted Breakthrough
Therapy Designation and Rare Pediatric Disease Designation by the
U.S. FDA. For additional information about the larotrectinib
clinical trials, please refer to www.clinicaltrials.gov.
Interested patients and physicians can contact the Loxo Oncology
Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123 or
visit www.loxooncologytrials.com.
About Loxo Oncology Loxo Oncology is
a biopharmaceutical company innovating the development of highly
selective medicines for patients with genetically defined cancers.
Our pipeline focuses on cancers that are uniquely dependent on
single gene abnormalities, such that a single drug has the
potential to treat the cancer with dramatic effect. We believe that
the most selective, purpose-built medicines have the highest
probability of maximally inhibiting the intended target, thereby
delivering best-in-class disease control and safety. Our management
team seeks out experienced industry partners, world-class
scientific advisors and innovative clinical-regulatory approaches
to deliver new cancer therapies to patients as quickly and
efficiently as possible. For more information, please visit the
company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company: Jacob S. Van Naarden Chief Business Officer
jake@loxooncology.com
Investors: Peter Rahmer The Trout Group, LLC 646-378-2973
prahmer@troutgroup.com
Media: Dan Budwick 1AB Media 973-271-6085
dan@1abmedia.com
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Aug 2024 to Sep 2024
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Sep 2023 to Sep 2024